| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on February 22, 2006
Accepted on April 5, 2006
Review |
1 Department of Laboratory Medicine, National Institutes of Health, Bldg 10, Room 2C-407, Bethesda, MD 20892
* To whom correspondence should be addressed. E-mail: ghortin{at}mail.cc.nih.gov.
Background: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF MS) and the related technique, surface-enhanced laser desorption/ionization (SELDI) TOF MS, are being applied widely to analyze serum or plasma specimens for potential disease markers.
Methods: Reports on the basic principles and applications of MALDI TOF MS were reviewed and related to information on abundance and masses of major plasma proteins.
Outcomes: MALDI TOF MS is a particle-counting method that responds to molar abundance, and ranking of plasma proteins by molar abundance increases the rank of small proteins relative to traditional ranking by mass abundance. Detectors for MALDI TOF MS augment the bias for detecting smaller components by yielding stronger signals for an equivalent number of small vs large ions. Consequently, MALDI TOF MS is a powerful tool for surveying small proteins and peptides comprising the peptidome or fragmentome, opening this new realm for analysis. It is complementary to techniques such as electrophoresis and HPLC, which have a bias for detecting larger molecules. Virtually all of the potential markers identified by MALDI TOF MS to date represent forms of the most abundant plasma proteins.
Conclusions: Analyses of serum or plasma by MALDI TOF MS provide new information mainly about small proteins and peptides with high molar abundance. The spectrum of observed proteins and peptides suggests value for applications such as assessment of cardiovascular risk, nutritional status, liver injury, kidney failure, and systemic immune responses rather than early detection of cancer. Extending analysis by MALDI TOF MS to lower abundance components, such as markers for early-stage cancers, probably will require more extensive specimen fractionation before analysis.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  C. Qian, J.-N. Liu, F. Tang, D. Yuan, Z. Guo, and J. Zhang A Novel Strategy for Proteome-wide Ligand Screening Using Cross-linked Phage Matrices J. Biol. Chem., March 26, 2010; 285(13): 9367 - 9372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Hortin, S. A. Carr, and N. L. Anderson Introduction: Advances in Protein Analysis for the Clinical Laboratory Clin. Chem., February 1, 2010; 56(2): 149 - 151. [Full Text] [PDF]
|
|
|
|
|
|
M. T. Davis, P. L. Auger, and S. D. Patterson Cancer Biomarker Discovery via Low Molecular Weight Serum Profiling--Are We Following Circular Paths? Clin. Chem., February 1, 2010; 56(2): 244 - 247. [Full Text] [PDF]
|
|
|
|
|
|
J. F. Timms, R. Cramer, S. Camuzeaux, A. Tiss, C. Smith, B. Burford, I. Nouretdinov, D. Devetyarov, A. Gentry-Maharaj, J. Ford, et al. Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer Clin. Chem., February 1, 2010; 56(2): 262 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Findeisen, M. Zapatka, T. Peccerella, H. Matzk, M. Neumaier, D. Schadendorf, and S. Ugurel Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling J. Clin. Oncol., May 1, 2009; 27(13): 2199 - 2208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Hortin, D. Sviridov, and N. L. Anderson High-Abundance Polypeptides of the Human Plasma Proteome Comprising the Top 4 Logs of Polypeptide Abundance Clin. Chem., October 1, 2008; 54(10): 1608 - 1616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Petrik, S. Saadoun, A. Loosemore, J. Hobbs, K. S. Opstad, J. Sheldon, E. Tarelli, F. A. Howe, B. A. Bell, and M. C. Papadopoulos Serum {alpha}2-HS Glycoprotein Predicts Survival in Patients with Glioblastoma Clin. Chem., April 1, 2008; 54(4): 713 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. McGuire, J. Overgaard, and F. Pociot Mass spectrometry is only one piece of the puzzle in clinical proteomics Briefings in Functional Genomics, February 28, 2008; (2008) eln005v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mantini, F. Petrucci, P. Del Boccio, D. Pieragostino, M. Di Nicola, A. Lugaresi, G. Federici, P. Sacchetta, C. Di Ilio, and A. Urbani Independent component analysis for the extraction of reliable protein signal profiles from MALDI-TOF mass spectra Bioinformatics, January 1, 2008; 24(1): 63 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hundt, U. Haug, and H. Brenner Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1935 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Findeisen, S. Post, F. Wenz, and M. Neumaier Addition of Exogenous Reporter Peptides to Serum Samples before Mass Spectrometry-Based Protease Profiling Provides Advantages over Profiling of Endogenous Peptides Clin. Chem., October 1, 2007; 53(10): 1864 - 1866. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Goldman, H. W. Ressom, M. Abdel-Hamid, L. Goldman, A. Wang, R. S. Varghese, Y. An, C. A. Loffredo, S. K. Drake, S. A. Eissa, et al. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum Carcinogenesis, October 1, 2007; 28(10): 2149 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Oncopeptidomics: A Useful Approach for Cancer Diagnosis? Clin. Chem., June 1, 2007; 53(6): 1004 - 1006. [Full Text] [PDF]
|
|
|
|
|
|
M. F. Lopez, A. Mikulskis, S. Kuzdzal, E. Golenko, E. F. Petricoin III, L. A. Liotta, W. F. Patton, G. R. Whiteley, K. Rosenblatt, P. Gurnani, et al. A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples Clin. Chem., June 1, 2007; 53(6): 1067 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Albrethsen Reproducibility in Protein Profiling by MALDI-TOF Mass Spectrometry Clin. Chem., May 1, 2007; 53(5): 852 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Hortin A New Era in Protein Quantification in Clinical Laboratories: Application of Liquid Chromatography-Tandem Mass Spectrometry Clin. Chem., April 1, 2007; 53(4): 543 - 544. [Full Text] [PDF]
|
|
|
|
|
|
E. H.J.M. Kemna, H. Tjalsma, V. N. Podust, and D. W. Swinkels Mass Spectrometry-Based Hepcidin Measurements in Serum and Urine: Analytical Aspects and Clinical Implications Clin. Chem., April 1, 2007; 53(4): 620 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Fiedler, S. Baumann, A. Leichtle, A. Oltmann, J. Kase, J. Thiery, and U. Ceglarek Standardized Peptidome Profiling of Human Urine by Magnetic Bead Separation and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Clin. Chem., March 1, 2007; 53(3): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wopereis, S. Grunewald, K. M.L.C. Huijben, E. Morava, R. Mollicone, B. G.M. van Engelen, D. J. Lefeber, and R. A. Wevers Transferrin and Apolipoprotein C-III Isofocusing Are Complementary in the Diagnosis of N- and O-Glycan Biosynthesis Defects Clin. Chem., February 1, 2007; 53(2): 180 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C.S. Cho, T. T.C. Yip, R. K.C. Ngan, T.-T. Yip, V. N. Podust, C. Yip, H. H.Y. Yiu, V. Yip, W.-W. Cheng, V. W.S. Ma, et al. ProteinChip Array Profiling for Identification of Disease- and Chemotherapy-Associated Biomarkers of Nasopharyngeal Carcinoma Clin. Chem., February 1, 2007; 53(2): 241 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Hortin, N. Seam, and G. T. Hoehn Bound Homocysteine, Cysteine, and Cysteinylglycine Distribution between Albumin and Globulins Clin. Chem., December 1, 2006; 52(12): 2258 - 2264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Rifai and R. E. Gerszten Biomarker Discovery and Validation Clin. Chem., September 1, 2006; 52(9): 1635 - 1637. [Full Text] [PDF]
|
|
|
|
|
|
M. Sanchez-Carbayo Antibody Arrays: Technical Considerations and Clinical Applications in Cancer Clin. Chem., September 1, 2006; 52(9): 1651 - 1659. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
